Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-CAR011
- Development stage
- Phase 1
- Lead developer
- The First Medical Center of Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
C-CAR011 is a proprietary, autologous chimeric antigen receptor T cell (CAR-T) therapy in which a patient's own T lymphocytes are genetically modified using a lentiviral vector to express a second-generation CAR targeting the tumor-associated antigen CD19. The construct includes undisclosed costimulatory signaling domains. C-CAR011 is designed to recognize and bind to CD19-expressing malignant B cells, leading to their destruction through cytolytic activity and cytokine release. It has been investigated primarily for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, as well as for acute lymphoblastic leukemia (ALL). Clinical studies have demonstrated safety and some durable responses in heavily pretreated patients[1][3][4][5].
- Other names
- autologous anti-CD19 chimeric antigen receptor T cells C-CAR011
02
Targets
Beyond the preview
Go deeper on C-CAR011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-CAR011.